BB-Cl-Amidine hydrochloride - 99%, high purity , CAS No.2436747-41-8

Item Number

B650942

Grouped product items
SKU	Size	Availability	Price
B650942-1mg	1mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$62.90
B650942-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$95.90
B650942-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$170.90
B650942-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$360.90
B650942-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$580.90
B650942-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$920.90

View related series

Basic Description

Specifications & Purity	≥99%
Biochemical and Physiological Mechanisms	BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor.
Storage Temp	Store at 2-8°C,Desiccated
Shipped In	Wet ice
Product Description	BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor In Vivo Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MRL/lpr mice . Dosage: 1 mg/kg. Administration: Subcutaneous injection daily from 8 to 14 weeks of age. Result: Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. Form:Solid IC50& Target:PAD

Canonical SMILES

O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N[C@H](C3=NC4=CC=CC=C4N3)CCCNC(CCl)=N.Cl

Molecular Weight

496.43

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description